LCB 07A
Alternative Names: LCB-07ALatest Information Update: 28 Mar 2026
At a glance
- Originator LegoChem Biosciences
- Developer LigaChem Biosciences
- Class Antibodies; Antineoplastics; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Mar 2026 No recent reports of development identified for research development in Haematological-malignancies in South Korea (Parenteral)
- 28 Mar 2026 No recent reports of development identified for research development in Solid-tumours in South Korea (Parenteral)
- 16 Feb 2022 LCB 07A is available for licensing as of 16 Feb 2022. https://www.legochembio.com/rnd/partners.php?lang=e